(+/-)-cis-1-(4-chlorophenyl)-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylic acid methyl ester

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: (+/-)-cis-1-(4-chlorophenyl)-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylic acid methyl ester
• 英文别名: (+/-) cis-methyl 1-(4-chlorophenyl)-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylate；methyl (1R,3R)-1-(4-chlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate
• 化学式: C₁₉H₁₇ClN₂O₂
• 分子量: 340.809
• InChiKey: XGVZWMNWLZHJDM-IAGOWNOFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  54.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+/-)-cis-1-(4-chlorophenyl)-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylic acid methyl ester 在 碳酸氢钠 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 16.0h， 生成 (6R,12aR)-2-ethyl-6-(4-chlorophenyl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
  参考文献：
  名称：

  功能化四氢-β-咔啉衍生物作为新型 PDE5 抑制剂的设计、合成和构效关系

  摘要：

  以他达拉非为模板，制备了一系列功能化的四氢-β-咔啉衍生物，并鉴定为新型强效选择性 PDE5 抑制剂。替换他达拉非第 6 位的 3,4-亚甲二氧基苯基，连同 N2-甲基取代基的延伸和两个手性碳的立体化学方面的操作，导致鉴定了化合物 XXI，一种高效的 PDE5 抑制剂（IC50 = 3毫）。与 PDE3B、PDE4B 和 PDE11A 相比，化合物 XXI 对 PDE5 也具有高度选择性，对 PDE5 的选择性指数为 52 和 235，而不是分别以 cAMP 和 cGMP 为底物的 PDE11。

  DOI：

  10.1002/ardp.201000236
• 作为产物：
  描述：

  DL-色氨酸 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 反应 10.0h， 生成 (+/-)-cis-1-(4-chlorophenyl)-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylic acid methyl ester
  参考文献：
  名称：

  Syntheses of new substituted triazino tetrahydroisoquinolines and β-carbolines as novel antileishmanial agents1

  摘要：

  A series of triazino tetrahydroisoquinolines (3-5) and beta-carboline derivatives (15-27) have been synthesized as novel antileishmanial agents. Among them, compounds 15, 16 and 25 have shown 78.0%, 78.6% and 68.0% in vivo inhibition against Leishmania donovani at a dose of 50 mg kg(-1) x 5 days, respectively, while compounds 3 and 18 exhibited 55.6% and 53.3% in vivo inhibitions, respectively, against L. donovani at a dose of 50 mg kg(-1) x 5 days. (c) 2005 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2005.09.007

文献信息

• Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors
  作者：Ahmed K. ElHady、Shou-Ping Shih、Yu-Cheng Chen、Yi-Chang Liu、Nermin S. Ahmed、Adam B. Keeton、Gary A. Piazza、Matthias Engel、Ashraf H. Abadi、Mohammad Abdel-Halim

  DOI：10.1016/j.bioorg.2020.103742

  日期：2020.5

  Herein we present the synthesis and characterization of a novel chemical series of tadalafil analogues that display different pharmacological profiles. Compounds that have the 6R, 12aR configuration and terminal carboxylic acid group at the side chain arising from the piperazinedione nitrogen were potent PDE5 inhibitors, with compound 11 having almost equal potency to tadalafil and superior selectivity

  在此，我们介绍了他达拉非类似物的新型化学系列的合成和表征，这些化学系列显示出不同的药理学特征。具有 6R、12aR 构型和由哌嗪二酮氮产生的侧链末端羧酸基团的化合物是有效的 PDE5 抑制剂，其中化合物 11 具有与他达拉非几乎相同的效力，并且比 PDE11（他达拉非最常见的脱靶）具有更高的选择性。将立体化学修饰为 6S、12aS 构型并采用异羟肟酸部分作为末端基团产生仅抑制 HDAC 的化合物。使用具有 6R、12aR 构型和异羟肟酸部分作为末端基团的化合物可以实现 PDE5/HDAC 双重抑制。针对不同来源的多种细胞系评估了合成化合物的抗癌活性。这些化合物对属于淋巴增殖性癌症以及实体瘤的细胞系具有抗癌活性。尽管之前的报道表明 PDE5 抑制剂具有抗癌活性，但这些化合物的生长抑制活性似乎仅依赖于 HDAC 抑制。化合物 26（泛 HDAC IC50 = 14 nM，PDE5 IC50 =
• Synthesis of Tadalafil Analogues
  作者：Liu‐Tang Wang、Hao Huang、Zhong‐Lin Ye、Yong Wu、Xue‐Chao Wang

  DOI：10.1080/00397910600764626

  日期：2006.9
• The Discovery of Tadalafil:  A Novel and Highly Selective PDE5 Inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1‘,2‘:1,6]pyrido[3,4-<i>b</i>]indole-1,4-dione Analogues
  作者：Alain Daugan、Pascal Grondin、Cécile Ruault、Anne-Charlotte Le Monnier de Gouville、Hervé Coste、Jean Michel Linget、Jorge Kirilovsky、François Hyafil、Richard Labaudinière

  DOI：10.1021/jm0300577

  日期：2003.10.1

  Modification of the hydantoin ring in the previously described lead compound 2a has led to the discovery of compound 12a, tadalafil, a highly potent and highly selective PDE5 inhibitor. The replacement of the hydantoin in compound 2a by a piperazinedione ring led to compound cis-11a which showed similar PDE5 inhibitory potency. Introduction of a 3,4-methylenedioxy substitution on the phenyl ring in position 6 led to a potent PDE5 inhibitor cis-11c with increased cellular potency. Optimization of the chain on the piperazinedione ring led to the identification of the racemic cis-N-methyl derivative 11i. High diastereospecificity for PDE5 inhibition was observed in the piperazinedione series with the cis-(6R,12aR) enantiomer displaying the highest PDE5 inhibitory activity. The piperazinedione 12a, tadalafil (GF196960), has been identified as a highly potent PDE5 inhibitor (IC50 = 5 nM) with high selectivity for PDE5 vs PDE1-4 and PDE6. Compound 12a displays 85-fold greater selectivity vs PDE6 than sildenafil 1.12a showed profound and long-lasting blood pressure lowering activity (30 mmHg/> 7 h) in the spontaneously hypertensive rat model after oral administration (5 mg/kg).
• The Discovery of Tadalafil:  A Novel and Highly Selective PDE5 Inhibitor. 1: 5,6,11,11a-Tetrahydro-1<i>H</i>-imidazo[1‘,5‘:1,6]pyrido[3,4-<i>b</i>]indole-1,3(2<i>H</i>)-dione Analogues
  作者：Alain Daugan、Pascal Grondin、Cécile Ruault、Anne-Charlotte Le Monnier de Gouville、Hervé Coste、Jorge Kirilovsky、François Hyafil、Richard Labaudinière

  DOI：10.1021/jm030056e

  日期：2003.10.1

  Starting from ethyl beta-carboline-3-carboxylate (beta-CCE), 1, a modest inhibitor of type 5 phosphodiesterase (PDE5), a series of functionalized tetrahydro-p-carboline derivatives has been identified as a novel chemical class of potent and selective PDE5 inhibitors. Optimization of the side chain on the hydantoin ring of initial lead compound 2 and of the aromatic ring on position 5 led to the identification of compound 6e, a highly potent and selective PDE5 inhibitor, with greater selectivity for PDE5 vs PDE1-4 than sildenafil. Compound 6e demonstrated a long-lasting and significant blood pressure lowering effect after iv administration in the spontaneously hypertensive rat model but showed only moderate oral in vivo efficacy.